Leiutis Pharma Announces CDSCO Approval for World's First Synthetic CBD Anxiety Therapy
Leiutis Pharmaceuticals has received CDSCO approval for the world's first synthetic CBD oral solution to treat mild to moderate anxiety disorders alongside cognitive behavioral therapy.
Leiutis Pharmaceuticals | 15/07/2026 | By News Bureau | 1804
Akums enters into joint association with Leiutis and Biophore for therapeutics
The partnership leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India
Leiutis Pharmaceuticals | 01/12/2022 | By Sudeep Soparkar | 1514
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy